A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials